SOURCE READING
Original and translation
The excerpt and translation use the primary source below. Further references inform SHIO’s analysis.
Primary source
- Original title
- NCI Patient-Derived Models Repository (PDMR)
- Original author / institution
- National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis
- Primary source
- National Cancer Institute, NIH
- Source language
- English
- Original publication date
- Original publication date not provided
Source: National Cancer Institute (NCI). Selected opening text, not the full page; no NCI logo or image is reproduced. The National Cancer Institute (NCI) does not endorse this translation and no endorsement by NCI should be inferred.
Basis for use：NCI text free of copyright; attribution and translation notice required
This edition uses the source language, so the original appears once.
The National Cancer Institute (NCI) has established a Patient-Derived Models Repository (PDMR) developed from human tumor tissues and blood. The models are made available upon request to serve as a resource for public-private partnerships and for academic cancer drug discovery efforts.These established, quality-controlled PDMs are clinically annotated with molecular information available in an easily accessible database. The model types include:
Patient-derived xenografts (PDXs)
Patient-derived in vitro tumor cell cultures (PDCs)
Patient-derived organoids (PDOrg)
Cancer associated fibroblasts (CAFs)
PDX panel tissue microarrays (TMAs)SHIO analysis
Cancer organoids need a traceable evidence history
The following is SHIO’s independent judgment and discussion of methods. It is separate from the source text and its translation.
SHIO reading note
Patient-derived tumour models connect experiments with human samples. That connection does not, by itself, establish a way to choose treatment for an individual. NCI’s repository and procedures make the underlying research infrastructure worth examining.
The central idea
SHIO puts traceability before the language of personalisation: who a model represents, what happened to it and which judgment its results can support.
Carry provenance with the result
NCI’s Patient-Derived Models Repository includes organoids among research models accompanied by clinical annotations and molecular information. It supports cancer drug discovery. Derivation from a human specimen should not be equated with validated prediction of that person’s treatment outcome.
SHIO proposes a short evidence history alongside every result: specimen context, model development, important versions and the purpose of the measurement. Unavailable details should remain explicitly unknown. A polished chart cannot carry a shared judgment if another researcher cannot trace its foundations.
Use procedures as a shared language
The NCI procedures directory lists separate organoid documents for thawing, culture, passaging and cryopreservation. Its July 16, 2026 update is a documentation date, not the date of a therapeutic discovery. This article examines the role of procedures without providing experimental instructions.
Before comparing outputs, teams should ask whether specimen types, processing, endpoints and quality decisions are comparable. Where conditions change, preserve version differences. New observations should not silently inherit the interpretation attached to an older workflow. This is a proposal for research governance.
Test clinical claims separately
If a project claims to support treatment selection, SHIO would ask it to specify the predicted outcome, comparison with observed outcomes, exclusions and responsibility for checking errors. These questions describe a validation task; they do not assign clinical capability to the repository itself.
Nor should readers assume that a particular model includes adequate immune, vascular or surrounding tissue features. Those properties require checking for the specific model. Making scope and responsibility explicit allows useful exploration without turning laboratory observations into individual prescribing advice.
A question for practice
For SHIO, patient origin creates a stronger duty of traceability. Models and procedures support research; clinical predictive value needs separate validation for the intended use. This is original editorial analysis, not an NCI translation or endorsement.
Research limits: findings depend on the study population and methods and do not establish an individual treatment benefit. This essay examines research and does not provide diagnosis or treatment advice.
REFERENCES & EDITORIAL NOTE
Sources & further reading
The source’s original title, author and basis for use appear in the source section. Excerpts, SHIO translations and independent analysis are clearly separated. References include the primary source and supporting material for checking the evidence and its context.
National Cancer Institute, NIH · Primary source
NCI Patient-Derived Models Repository (PDMR)
Original source date：No publication date providedAccessed：NCI Reuse of Text says NCI product text is free of copyright unless otherwise indicated, requires NCI credit and an original-title link for digital reproduction. The opening PDMR institutional text has no separate copyright credit. NCI Translations policy requires the exact non-endorsement statement included in the notices. No image, logo, PDQ trademark or external paper is copied. Policy/source: https://www.cancer.gov/policies/copyright-reuse Selected original excerpt and SHIO translation only, not full reproduction. No institutional endorsement.
National Cancer Institute, NIH
Patient-Derived Models Repository SOPs
Original source date：No publication date providedAccessed：NCI text is free of copyright unless otherwise indicated; source credit and original-title link required. Original editorial analysis, no full translation; no NCI endorsement.